Difference between revisions of "Succinylcholine"
From WikiAnesthesia
Chris Rishel (talk | contribs) |
m (add absolute contraindications) |
||
| (One intermediate revision by one other user not shown) | |||
| Line 1: | Line 1: | ||
{{Infobox drug reference | {{Infobox drug reference | ||
| trade_names =Anectine | | trade_names = Anectine | ||
| drug_class =Depolarizing neuromuscular blocker | | drug_class = Depolarizing neuromuscular blocker | ||
| drug_class_color =succinylcholine | | drug_class_color = succinylcholine | ||
| uses =Paralysis for intubation | | uses = Paralysis for intubation | ||
| contraindications =History/risk of [[Malignant hyperthermia|malignant hyperthermia]]<br /> | | contraindications = History/risk of [[Malignant hyperthermia|malignant hyperthermia]]<br /> | ||
Conditions which proliferate extrajunctional acetylcholine receptors | Conditions which proliferate extrajunctional acetylcholine receptors | ||
| routes =Intravenous, intramuscular | | routes = Intravenous, intramuscular | ||
| dosage = | | dosage = | ||
|halflife_elimination=|image_file=Succinylcholine.svg|protein_binding=|clearance=|time_onset=30-60 seconds (IV)<br /> | | halflife_elimination = | ||
2-3 minutes (IM)|halflife_redistribution=|metabolism=Plasma cholinesterase|duration=5-10 minutes (IV)<br /> | | image_file = Succinylcholine.svg | ||
10-30 minutes (IM)|adverse_effects=Bradycardia, hyperkalemia, malignant hyperthermia, myalgias|mechanism=Depolarizing blockade of neuromuscular junction|formula=}} | | protein_binding = | ||
| clearance = | |||
| time_onset = 30-60 seconds (IV)<br /> | |||
2-3 minutes (IM) | |||
| halflife_redistribution = | |||
| metabolism = Plasma cholinesterase | |||
| duration = 5-10 minutes (IV)<br /> | |||
10-30 minutes (IM) | |||
| adverse_effects = Bradycardia, hyperkalemia, malignant hyperthermia, myalgias | |||
| dosage_calculation = succinylcholine | |||
| mechanism = Depolarizing blockade of neuromuscular junction | |||
| formula = | |||
}} | |||
'''Succinylcholine''', also known as '''suxamethonium''', is a short-acting neuromuscular blocker used during intubation. | '''Succinylcholine''', also known as '''suxamethonium''', is a short-acting neuromuscular blocker used during intubation. | ||
| Line 19: | Line 31: | ||
===Absolute contraindications<!-- List absolute contraindications for use of the drug. If none, this section may be removed. -->=== | ===Absolute contraindications<!-- List absolute contraindications for use of the drug. If none, this section may be removed. -->=== | ||
* hyperkalemia | |||
* increased risk of [[Malignant Hyperthermia|malignant hyperthermia]] | |||
* open globe injury | |||
* allergy | |||
===Precautions<!-- List precautions for use of the drug. If none, this section may be removed. -->=== | ===Precautions<!-- List precautions for use of the drug. If none, this section may be removed. -->=== | ||
Latest revision as of 16:41, 17 July 2022
Succinylcholine
| Trade names |
Anectine |
|---|---|
 | |
| Clinical data | |
| Drug class |
Depolarizing neuromuscular blocker |
| Uses |
Paralysis for intubation |
| Contraindications |
History/risk of malignant hyperthermia |
| Routes of administration |
Intravenous, intramuscular |
| Dosage | |
|
|
| Pharmacodynamics | |
| Mechanism of action |
Depolarizing blockade of neuromuscular junction |
| Adverse effects |
Bradycardia, hyperkalemia, malignant hyperthermia, myalgias |
| Pharmacokinetics | |
| Onset of action |
30-60 seconds (IV) |
| Duration of action |
5-10 minutes (IV) |
| Metabolism |
Plasma cholinesterase |
| Physical and chemical data | |
| Article quality | |
| Editor rating | |
| User likes | 0 |
Succinylcholine, also known as suxamethonium, is a short-acting neuromuscular blocker used during intubation.
Uses
Contraindications
Absolute contraindications
- hyperkalemia
- increased risk of malignant hyperthermia
- open globe injury
- allergy
Precautions
Pharmacology
Pharmacodynamics
Mechanism of action
Adverse effects
Pharmacokinetics
Chemistry and formulation
History
References
Top contributors: Chris Rishel and huckfinne@gmail.com